Person
Jennifer Doudna
Jennifer Doudna appears on the Conversations with Mike Milken podcast (Episode 119), where she discussed the work of the Innovative Genomics Institute, CRISPR gene editing, and COVID-19 testing and vaccines. The institute is based at the University of California, Berkeley, in partnership with the University of California, San Francisco.
In 2020, the institute set up a clinical COVID testing lab in three weeks and had processed well over 100,000 samples by the time of the interview. Doudna said RNA vaccines moved quickly because of earlier research, and she cautioned that correcting BRCA1 mutations to protect against breast cancer is not a year away.
1 episodes · 14 quoted claims
The Innovative Genomics Institute is based at the University of California, Berkeley, in partnership with the University of California, San Francisco.
“I'm excited to have an institute established now at the University of California, Berkeley, and in partnership with the University of California, San Francisco”
Conversations with Mike Milken · 0:04:40
The Innovative Genomics Institute set up a clinical COVID testing lab in three weeks in early 2020 and published a guide to doing so.
“the IGI was able to institute a clinical testing lab in three weeks, we got a pop up lab going, and we've published how to do that.”
Conversations with Mike Milken · 0:05:22
The Innovative Genomics Institute's testing lab had processed well over 100,000 clinical samples for COVID-19 by the time of this interview.
“since then, we've now tested well over 100 ,000 clinical samples for COVID-19 diagnosis.”
Conversations with Mike Milken · 0:05:53
The Innovative Genomics Institute worked with community health groups to provide COVID testing to people in homeless encampments, nursing homes and frontline jobs who would otherwise lack access.
“So this means people living in homeless encampments, nursing homes, and many frontline workers.”
Conversations with Mike Milken · 0:05:53
The Innovative Genomics Institute routinely tests police, fire support personnel and California Energy Commission workers for COVID-19.
“So we routinely now test our our police, our fire support personnel, California Energy Commission, the people keeping the lights on around the state of California.”
Conversations with Mike Milken · 0:05:53
Doudna noted that two RNA-based COVID-19 vaccines looked highly effective in early studies within about a year of the virus becoming known.
“it's extraordinary to think that a year ago, we didn't even know about this virus, And now we have two different RNA-based vaccines that look highly effective in these early studies.”
Conversations with Mike Milken · 0:07:56
Doudna attributed the speed of the RNA vaccines to earlier academic and company research on RNA as a delivery vehicle that induces an immune response.
“Because of fundamental research that was done years ago in an academic setting and then later in companies to develop RNA as a delivery vehicle, and it's very effective in inducing an immune response.”
Conversations with Mike Milken · 0:07:56
Doudna said the sequence of the entire human genome has been available for about two decades.
“We have the sequence of the entire human genome now that's been available for the last two decades.”
Conversations with Mike Milken · 0:03:13
The Innovative Genomics Institute holds an annual visitor's day where people of all ages can learn about its work.
“we have a visitor's day every year where we welcome people of all ages to come in and talk to us, find out who we are, what we're doing, and give us feedback.”
Conversations with Mike Milken · 0:09:17
Doudna described the idea of using genome editing to give people a protective gene that some lucky people inherit naturally, which protects against high cholesterol.
“The idea that one could use genome editing to give all of us a protective gene that is known to, and a few lucky people that inherit this naturally, have a protection against high cholesterol.”
Conversations with Mike Milken · 0:14:20
Doudna cautioned that correcting BRCA1 mutations to protect against breast cancer is not a year away.
“I don't want people to come away from this conversation thinking that we're a year away from being able to correct BRCA1 mutations in people that would give them protection against breast cancer, for example.”
Conversations with Mike Milken · 0:14:55
Doudna said a key need is to deploy CRISPR inside patients' bodies, called in situ, rather than editing cells in a lab and returning them.
“we do need to figure out how to deploy CRISPR in clinical settings to patients in situ, meaning in their body, without having to take cells out to do the editing in the lab and then put them back.”
Conversations with Mike Milken · 0:15:31
Doudna said the Innovative Genomics Institute places plant biologists next to researchers working on T cell therapies, which produced useful exchange of ideas.
“You might not have expected that there would be obvious value in having plant biologists working right next door to people that are doing T cell therapies.”
Conversations with Mike Milken · 0:18:28
Doudna said Berkeley has no medical school, yet the Innovative Genomics Institute could build a clinical lab because of its staff and infrastructure and its work with regulators.
“We don't have a medical school. Why were we able to do that? Honestly, it was because we had the staff and the infrastructure at the IGI”
Conversations with Mike Milken · 0:19:43